Impact of diabetic retinopathy on late cardiac events after percutaneous coronary intervention  by Tanaka, Akihito et al.
OI
p
A
N
Y
D
a
A
R
R
1
A
A
K
D
L
P
I
c
t
d
R
o
p
c
H
l
(
a
T
0
hJournal of Cardiology 64 (2014) 175–178
Contents lists available at ScienceDirect
Journal of Cardiology
journa l homepage: www.e lsev ier .com/ locate / j j cc
riginal article
mpact of diabetic retinopathy on late cardiac events after
ercutaneous coronary intervention
kihito Tanaka (MD) ∗, Hideki Ishii (MD, PhD), Yosuke Tatami (MD), Yohei Shibata (MD),
aohiro Osugi (MD), Tomoyuki Ota (MD), Satoshi Okumura (MD), Susumu Suzuki (MD),
osuke Inoue (MD), Toyoaki Murohara (MD, PhD)
epartment of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
r t i c l e i n f o
rticle history:
eceived 28 October 2013
eceived in revised form
4 December 2013
ccepted 19 December 2013
vailable online 5 February 2014
eywords:
iabetic retinopathy
ate cardiac events
a b s t r a c t
Background:Diabetic retinopathyhasbeen identiﬁedas apredictorof cardiovascular events andheart fail-
ure in patientswith diabetesmellitus (DM). This study aimed to assess the impact of diabetic retinopathy
on the incidence of late cardiac events following percutaneous coronary intervention.
Methods:Weenrolled 88 consecutive DMpatientswho underwent elective percutaneous coronary inter-
vention and whose ophthalmologic records were available. Patients were divided into 2 groups: those
withdiabetic retinopathy (DR+group;n=47), and thosewithoutdiabetic retinopathy (DR−group;n=41).
We examined the incidence of major adverse cardiac events (MACE) including cardiac death, myocardial
infarction, and acute heart failure requiring emergency admission over a period of up to 5 years.
Results: Patients in the DR+ group were likely to have a lower estimated glomerular ﬁltration rate.ercutaneous coronary intervention Kaplan–Meier analysis showed that the event-free survival rates for all MACE, myocardial infarction,
and heart failure were signiﬁcantly lower in the DR+ group than in the DR− group (p=0.002, p=0.025,
and p=0.022, respectively). Multivariate Cox proportional hazards analysis indicated that the presence
of DR was a signiﬁcant predictor of MACE (hazard ratio: 8.7; 95% CI: 1.1–69.8, p=0.042).
Conclusion: The presence of DR might be a useful predictor of late cardiac events following percutaneous
coronary intervention.
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Diabetic retinopathy (DR) is a common microvascular diabetic
omplication. Previous epidemiologic studies have demonstrated
hat the presence of DR is associated with an increased risk of car-
iovascular events in patients with diabetes mellitus (DM) [1,2].
eports have shown that the presence of DR confers an excess risk
f heart failure, independent of known risk factors [3,4].
Furthermore, some observational studies have shown that the
resence of DR in coronary artery disease patients is related to
ardiovascular events following coronary revascularization [5–7].
owever, the availability of data on an association between DR and
ate cardiac events following percutaneous coronary intervention
PCI) is limited.
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Therefore, the aim of this study was to examine the association
between the presence of DR and late cardiac events following PCI
in Japanese DM patients.
Methods
Patients
We identiﬁed 187 consecutive DM patients who underwent
elective PCI at our institution between January 2006 andDecember
2011. Criteria for DMweremet if patients had hemoglobin A1c lev-
els (National Glycohemoglobin Standardization Program) ≥6.5%, a
fasting plasma glucose concentration >126mg/dL, and/or a history
of anti-hyperglycemic medication or previous diagnosis of dia-
betes. Ophthalmologic recordswere obtained for 88 of the patients,
and these comprised the study cohort. The88patientsweredivided
into the following 2 groups: those with DR (DR+ group; n=47),
and those without diabetic retinopathy (DR− group; n=41). DR
was deﬁned as the presence of typical eye changes, including
hemorrhages,microaneurysms, exudates, andﬁbrousproliferation,
laser marks, a previous history of vitreous hemorrhage, and reti-
nal surgery. The patient databasewas developed prospectively and
vier Ltd. All rights reserved.
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Table 1
Baseline patient characteristics.
DR+ (n=47) DR− (n=41) p-Value
Age (years) 66±11 69±8 0.196
Male, n (%) 42 (89%) 28 (68%) 0.015
Hypertension, n (%) 39 (83%) 27 (66%) 0.064
Dyslipidemia, n (%) 39 (83%) 32 (78%) 0.559
Diabetes mellitus, n (%) 47 (100%) 41 (100%) –
Hemoglobin A1c, % 7.6±1.2 7.2±1.1 0.103
Status of diabetic retinopathy, n
Mild to moderate
non proliferative
23 –
Severe non
proliferative
7 –
Proliferative 17 –
Duration of diabetes
mellitus, (years)
20±9 11±9 <0.001
Current smoking, n (%) 12 (26%) 12 (29%) 0.678
eGFR (mL/min/1.73m2) 50.1±26.5 68.3±23.3 0.001
eGFR <60, n (%) 26 (55%) 15 (37%) 0.079
Prior myocardial
infarction, n (%)
9 (19%) 3 (7%) 0.129
Prior CABG, n (%) 9 (19%) 2 (5%) 0.056
LVEF, % 60.5±13.7 67.0±7.4 <0.01
E/e′ 15.6±5.7 13.5±5.0 0.123
Target lesion, n (%)
Left main trunk 0 (0%) 0 (0%) 0.205
Left anterior
descending artery
22 (47%) 23 (56%)
Left circumﬂex artery 4 (9%) 7 (17%)
Right coronary artery 19 (40%) 11 (27%)
Graft 2 (4%) 0 (0%)
DES use, n (%) 21 (45%) 18 (44%) 0.942
Residual SYNTAX score, n
0–8 28 26 0.501
9+ 10 13
Medication, n (%)
Aspirin 46 (98%) 41 (100%) 1
Thienopyridine 39 (83%) 33 (80%) 0.762
Statin 29 (62%) 23 (56%) 0.594
ACEI/ARB 33 (70%) 24 (59%) 0.253
-Blocker 14 (30%) 7 (17%) 0.163
Ca-antagonist 26 (55%) 20 (49%) 0.54
Insulin 25 (53%) 16 (39%) 0.184
Sulfonylurea 13 (28%) 12 (29%) 0.867
Alpha-glucosidase
inhibitor
13 (28%) 16 (39%) 0.258
DPP-4 inhibitor 3 (6%) 4 (10%) 0.423
Biganide 11 (23%) 6 (15%) 0.299
Glitazone 5 (11%) 3 (7%) 0.436
Glinide 1 (2%) 4 (10%) 0.141
eGFR, estimated glomerular ﬁltration rate; CABG, coronary artery bypass grafting;
LVEF, left ventricular ejection fraction; DES, drug-eluting stent; ACEI, angiotensin-76 A. Tanaka et al. / Journal o
linical data were analyzed retrospectively. This study was per-
ormed according to the guidelines of the Declaration of Helsinki,
nd all subjects gave their informed consent to participate in this
tudy, which was approved by the local Ethics Committee.
linical outcomes
The primary endpoint was the occurrence of a major adverse
ardiac event (MACE), deﬁned as a composite of cardiac death,
yocardial infarction, and acute heart failure requiring emergency
dmission. Myocardial infarction was deﬁned as an event with a
ew elevation in serum creatine kinase and/or evolutionary ST ele-
ation, the development of new Q waves, or the presence of left
undle branch block. Patients were followed for up to 5 years.
ther deﬁnitions
Estimated glomerular ﬁltration rate (eGFR) was calculated
sing the revised Japanese equation: eGFR (mL/min/1.73m2) =
94× serum creatinine−1.094 × age−0.287 ×0.739 (in females) [8].
eft ventricular ejection fraction (LVEF) was assessed using
chocardiography. Hypertension was deﬁned as systolic/diastolic
lood pressure (SBP/DBP) >140/90mmHg, or as having received
reatment for hypertension. Duration of diabetes was deﬁned as
he period from ﬁrst diagnosis of DM to PCI procedure. The resid-
al SYNTAX (Synergy between PCIwith Taxus and Cardiac Surgery)
core, determined as the SYNTAX score remaining after PCI, was
ssessed in patients without coronary artery bypass graft history
9].
tatistical analysis
Data are presented as mean± SD. Categorical variables are
xpressed as counts and percentages. Continuous data were com-
ared by using unpaired t-tests. Categorical data were compared
sing the 2 test. Cumulative survival rates in each group were
nalyzed using the Kaplan–Meier method, and the survival rate
ifferences between the groups were estimated using the log-
ank test. Hazard ratios (HRs) and 95% conﬁdence intervals (95%
Is) were calculated for each factor using Cox univariate analysis.
ox multivariate regression analysis was performed to determine
ndependent predictors of MACE. Factors with p<0.2 on univariate
nalysiswere entered into themultivariate Cox regression analysis.
p-value <0.05 was considered statistically signiﬁcant. All analy-
es were performed using the SPSS 18.0 software package (SPSS,
hicago, IL, USA).
esults
The baseline characteristics of all patients are shown in Table 1.
here were signiﬁcantly more males in the DR+ group than in the
R− group. No signiﬁcant differences were observed between the
roups with regard to age, the presence of hypertension or dysli-
idemia, and smoking status. The patients in DR+ group had longer
uration of DM. Insulin use and hemoglobin A1c levels tended to
e higher in the DR+ group than in the DR− group, but the differ-
nces were not signiﬁcant. The mean eGFR level in the DR+ group
as signiﬁcantly lower than that in the DR− group. Rates of med-
cation use did not signiﬁcantly differ between the groups. LVEF,
etermined using echocardiography, was lower in the DR+ group
han in the DR− group.
The 88 eligible patients were followed for a mean of 1057±583
ays. The cumulative MACE-free survival rate was calculated for
oth groups using the Kaplan–Meier method (Fig. 1a). The MACE-
ree survival rate was signiﬁcantly lower in the DR+ group than
n the DR− group (p=0.002). The cumulative event-free survivalconverting enzyme inhibitor; ARB, angiotensin receptor II blocker; DPP, dipeptidyl
peptidase.
curves for cardiac death, myocardial infarction, and acute heart
failure requiring emergency admission are shown in Fig. 1b–d,
respectively. Event-free survival for cardiac death tended to be
lower in the DR+ group than in the DR− group (p=0.056). Event-
free survival rates for both myocardial infarction and heart failure
were signiﬁcantly lower in the DR+ group than in the DR− group
(p=0.025 and p=0.022, respectively). Table 2 shows the details of
events during follow-up.
Multivariate Cox proportional hazard analysis indicated that
the presence of DR was a signiﬁcant and independent predictor
of MACE (HR: 8.7; 95% CI: 1.1–69.8, p=0.042; Table 3).
DiscussionDR is a common microvascular diabetic complication. In this
study, we showed that the presence of DRwas a signiﬁcant predic-
tor of late cardiac events following PCI.
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Fig. 1. (a) The cumulative MACE-free survival rate was calculated for both groups using the Kaplan–Meier method. The MACE-free survival rate was signiﬁcantly lower in
the DR+ group than in the DR− group (p=0.002). (b) Event-free survival rate for cardiac
Event-free rate for myocardial infarction was signiﬁcantly lower in the DR+ group than
lower in the DR+ group than in the DR− group (p=0.022). DR, diabetic retinopathy; MAC
Table 2
Incidence of MACE during follow-up.
DR+ (n=47) DR− (n=41)
MACE, n 12 1
Cardiac death 4 0
Myocardial infarction 5 0
Acute heart failure requiring
emergency admission
8 1
MACE, major adverse cardiac events; DR, diabetic retinopathy.
T
P
H
hable 3
redictors for MACE: Cox proportional hazards analysis.
Univariate
HR (95% CI)
Male 1.379 (0.305–6.230)
Age 1.001 (0.945–1.061)
Hypertension 1.883 (0.417–8.501)
Dyslipidemia 1.190 (0.263–5.378)
Current smoking 1.781 (0.519–6.108)
Prior myocardial infarction 1.737 (0.474–6.371)
Prior CABG 1.715 (0.376–7.810)
Body mass index 1.084 (0.945–1.243)
eGFR 0.979 (0.959–0.998)
LVEF 0.963 (0.925–1.003)
E/e′ 1.027 (0.899–1.173)
HbA1c 0.999 (0.647–1.544)
The presence of DR 11.966 (1.550–92.357)
R, hazard ratio; CI, conﬁdence interval; CABG, coronary artery bypass grafting; eGFR,
emoglobin; DR, diabetic retinopathy.death tended to be lower in the DR+ group than in the DR− group (p=0.056). (c)
in the DR− group (p=0.025). (d) Event-free rate for heart failure was signiﬁcantly
E, major adverse cardiac events.
Several epidemiologic studies have shown that the presence
of DR is associated with increased all-cause and cardiovascular
mortality risk in diabetic patients [1,2,10]. According to a recently
reported meta-analysis of 20 observational studies, the presence
of any degree of DR in patients with type 2 diabetes increases
the chance of all-cause mortality and/or cardiovascular events
by 2.34 times as compared with diabetic patients without DR
[1].
The presence of DR has also been shown to be a predictor of
heart failure, independent of preexisting coronary heart disease
[3,4]. Cheung et al. demonstrated that the presence of DR was
associated with concentric remodeling independent of traditional
Multivariate
p-Value HR (95% CI) p-Value
0.676
0.966
0.410
0.821
0.359
0.405
0.486
0.249
0.033 0.986 (0.966–1.008) 0.207
0.070 0.977 (0.938–1.018) 0.265
0.693
0.998
0.017 8.705 (1.086–69.76) 0.042
estimated glomerular ﬁltration rate; LVEF, left ventricular ejection fraction; Hb,
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isk factors and coronary atherosclerosis, by measuring LV mass
nd volumewith cardiacmagnetic resonance imaging [11]. Takeda
t al. have shown an association between DR and LV diastolic
ysfunction by assessing the diastolic index of echocardiographic
olor kinesis [12]. DR is a microvascular complication, and its
resence appears to reﬂect the dysfunctioning of the coronary
icrocirculation to some extent. The above reports may in part
xplain the increased incidence of heart failure in DMpatientswith
R.
As described above, the presence of DR predicts long-term
ardiovascular events and heart failure in diabetic patients. Fur-
hermore, some studies have reported an association between
ardiac events and DR in DM patients with coronary artery dis-
ase receiving coronary revascularization [5–7,13]. However, the
umber of such reports is limited and further data on this issue
re needed. In this Japanese cohort study, we showed that the
resence of DR was an independent predictor of late adverse
ardiac events, including cardiac death, myocardial infarction,
nd acute heart failure requiring emergency admission follow-
ng PCI. Furthermore, patients with DR had signiﬁcantly higher
ncidence rates of both myocardial infarction and heart failure
hen each event was analyzed separately. The occurrence of
ardiac death tended to be higher in patients with DR than in
hose without DR. We consider the absence of a statistically
igniﬁcant difference between the groups in the case of car-
iac death to be a consequence of our small patient sample.
ccording to our results, the presence of DR could predict late
ardiac events following elective PCI. DR is still not widely used
s a common predictive marker. However, we should assess the
resence of DR in diabetic patients receiving PCI and consider
he DR patients as subjects who require more careful follow-
p.
The presence of even mild chronic kidney disease (CKD) is
n established predictor of adverse prognosis after PCI [14–18].
n this study, patients with DR had lower eGFR levels and
ended to have a higher prevalence of CKD than those without
R. However, the presence of DR remained a signiﬁcant pre-
ictor of late cardiac events following PCI after adjustment for
GFR.
Our study has several limitations. First, this was a sin-
le center study with a relatively small population. Second,
e excluded patients for whom we could not obtain the
esults of ophthalmologic examination. Largemulticenter prospec-
ive clinical investigations are required to further explore this
ssue.
In conclusion, we showed that the presence of DR was a signif-
cant predictor of late cardiac events following PCI. This result can
e of beneﬁt in daily clinical practice, and ophthalmologic exami-
ation for the detection of DRmight be required as routine practice
n diabetic patients undergoing PCI.
[iology 64 (2014) 175–178
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